Informuta, Inc.
StreetZero Signal 61
About Informuta, Inc.
Informuta, Inc. specializes in providing advanced solutions for forecasting treatment-emergent antimicrobial resistance, equipping healthcare professionals with tools to enhance patient care. Founded in 2023 by CEO Kalen Hall and CTO Leo Williams, the company develops technology that predicts antimicrobial resistance patterns. It maintains a presence at Johnson & Johnson Innovation Labs (JLABS) in San Diego and has received NSF grants for its research.
LATEST FUNDINGPrivate Placement
$713K
Announced 2026-11-05
TOTAL RAISED$1.27M
IN THE NEWS
EMPLOYEES—
FOUNDED2023
HQSan Diego, California, United States
Industry
Other Technology
Tags
BiotechnologyHealthcareAntimicrobial ResistanceSeed
Investors
Key highlights
- Raised Seed funding in March 2026 co-led by Community Development Venture Capital Alliance and New Orleans BioFund.
- Received multiple NSF grants including $275K and a Phase II award for antimicrobial resistance research.
- Established JLABS residency in San Diego for facilities and mentorship.
- Won 1st Place at Tulane Demo Day.
- Focuses on predictive technology for treatment-emergent antimicrobial resistance.
Ask StreetZero about Informuta, Inc.
Put our AI to work on this deal.
Similar companies
Other Other Technology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account